19646-07-2

Basic information

• Product Name: 2,4-Dichloro-5-methoxypyrimidine
• Synonyms: 2,4-Dichloro-5-methoxy-1,3-diazine, 2,4-Dichloropyrimidin-5-yl methyl ether;2,4- twochloro -5-MethoxypyriMidine;5-METHOXY-2,4-DICHLORO PYRIMIDINE;SPECS AO-324/25087002;2,4-AICHLORO-5-METHOXY PYRIMIDINE;2,4-Dichloro-5-methoxpyrimidine;2,4-DICHLORO-5-METHOXYPYRIMIDINE, 98+%;2,4-Dichloro-5-methoxypyrimidine
• CAS NO: 19646-07-2
• Molecular Formula: C₅H₄Cl₂N₂O
• Molecular Weight: 179
• EINECS: 1312995-182-4
• Product Categories: Heterocycle-Pyrimidine series;APIs & Intermediate;Pyrimidine;Pyridines, Pyrimidines, Purines and Pteredines;Building Blocks;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrimidines;PyrimidinesHeterocyclic Building Blocks;Aromatics;Heterocycles
• Mol File: 19646-07-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 68 °C
• Boiling Point: 259.9 °C at 760 mmHg
• Flash Point: 111 °C
• Appearance: /
• Density: 1.446 g/cm³
• Vapor Pressure: 0.0204mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -2.67±0.29(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2,4-Dichloro-5-methoxypyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-5-methoxypyrimidine(19646-07-2)
• EPA Substance Registry System: 2,4-Dichloro-5-methoxypyrimidine(19646-07-2)

Safety Data

• Hazard Codes: Xi,C,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT, CORROSIVE
• Hazardous Substances Data: 19646-07-2(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 19646-07-2 differently. You can refer to the following data:
1. 2,4-Dichloro-5-methoxypyrimidine can be used for preparation of heteroarylpiperazine derivatives for use in treatment of Alzheimer's disease.
2. It is used for preparation of heteroarylpiperazine derivatives for use in treatment of Alzheimer's disease.

InChI:InChI=1/C5H4Cl2N2O/c1-10-3-2-8-5(7)9-4(3)6/h2H,1H3

Upstream product

• 6623-81-0 5-methoxyuracil 
• 6623-81-0 5-Methoxypyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 98021-95-5 2-Chloro-4-hydrazino-5-methoxy-pyrimidine 
• 1042434-81-0 2-{[2-chloro-5-(methoxy)-4-pyrimidinyl]amino}benzamide 
• 1042434-82-1 2-[(2-chloro-5-methoxypyrimidin-4-yl)amino]-N-methylbenzamide 
• 1333240-17-7 2-chloro-4,5-dimethoxypyrimidine 
• 1333240-08-6 5-methoxy-3-methyl-2-(4-phenoxyphenyl)pyrimidin-4(3H)-one 
• 1333240-06-4 2-[4-chloro-3-(trifluoromethyl)phenyl]-5-methoxy-3-methylpyrimidin-4(3H)-one 
• 1313718-71-6 4-(5-methoxy-4-morpholin-4-ylpyrimidin-2-yl)benzene-1,2-diamine 
• 1313718-69-2 4-(5-methoxy-4-morpholin-4-ylpyrimidin-2-yl)-2-nitrophenylamine 
• 1313718-44-3 4-[5-methoxy-2-(3-nitrophenyl)pyrimidin-4-yl]morpholine 

Relevant articles and documents

Experimental measurement and correlation of the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane at temperatures between (295 and 320) K

The solid-liquid equilibrium of 2,4-dichloro-5-methoxypyrimidine was first determined in this article. Using a laser monitoring observation technique, the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane have been determined experimentally from (295.60 to 316.39, 302.37 to 316.95, 299.44 to 316.61, 297.35 to 311.37, 298.60 to 312.15, and 298.10 to 320.08) K, respectively. The results are correlated with λ-h equation and Apelblat equation. The calculated results show that the correlation of the Apelblat model for six measured systems has less deviation than that of the λ-h equation.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV

The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.

COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein R1 is CN; R2 is H or F; R3 and R4 are independently hydrogen, fluorine, chlorine or OR5; R5 is hydrogen, C1-6 alkyl, C1-6 alkenyl or C1-6 alkynyl; R6 and R7 are independently hydrogen, halogen, OR8 or NR9R10; R8 is hydrogen or C1-6 alkyl; R9 and R10 are independently hydrogen or C1-6 alkyl; or the groups R9 and R10 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR8, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C1-6 alkoxy; or the groups R9 and R10 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C1-6 alkoxy, is provided. The use of such compounds in treating amyloid-related disease is also disclosed.